

TRAIL/TNFSF10 Protein, Mouse, Recombinant

General Information

Synonyms:	Protein TRAIL;TNF-related apoptosis-inducing ligand;CD_antigen: CD253;Tumor necrosis factor ligand superfamily member 10;Tnfsf10
Protein Construction:	Arg119-Asn291
Species:	Mouse
Expression Host:	E. coli
Accession:	P50592
Molecular Weight:	~20 kDa (Reducing conditions)

QC Testing

Biological Activity:	ED 50 < 100.0 ng/ml, measured by the cell growth inhibitory assay using RPMI-8226 cells, corresponding to a specific activity of > 1.0 × 10 ⁴ units/mg.
Purity:	> 98% as determined by SDS-PAGE
Endotoxin:	< 0.2 EU/μg of protein as determined by the LAL method.
Formulation:	Lyophilized from a 0.2 μm filtered solution in PBS.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in sterile deionized water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

TNF-related apoptosis-inducing ligand (TRAIL), also known as Tumor Necrosis Factor Super-Family 10 (TNFSF10) or apoptosis 2 ligand (Apo2L), is a pleiotropic cytokine that belongs to the TNF superfamily. Full length TRAIL expressed in vivo is a type II transmembrane protein, although the soluble form also exists and functions. TRAIL has four major receptors: two death receptors DR4 and DR5, and two decoy receptors Dcr1 and Dcr2. TRAIL binds to the death receptors which recruits the FAS-associated death domain and activates caspases 8 and 10 which eventually leads to apoptosis. Because of its antitumor potential, TRAIL is actively studied as a therapeutic agent.

On the other hand, abnormal expression of TRAIL in small arteries can induce the proliferation of smooth muscle cells, thereby increasing vascular remodeling and pulmonary arterial hypertension.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481